Skip To Content

Sharing perspectives leads to greater understanding and fuels innovation.

The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.

June 09, 2021 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
May 25, 2021 · Public Policy & Regulatory Affairs Team
On May 24, 2021 the New York Workers’ Compensation Board (WCB) announced a delay of OnBoard-Limited Release via bulletin 046-1408. Read more...
May 18, 2021 · Policy Matters team
Listed below are brief updates on several recent policy developments across the country. Read more...
May 12, 2021 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved a higher-dose naloxone hydrochloride nasal spray – Kloxxado™ (8 mg) – on April 30, 2021. Naloxone is indicated for the emergency treatment of known or suspected opioid analgesic overdose, as manifested by respiratory and/or central nervous system (CNS) depression, for adults and pediatric patients. Read more...
May 06, 2021 · Clinical Team
Pregabalin extended-release (ER) tablets, the generic formulation of Lyrica® CR, was released on April 13, 2021, according to the U.S. Food and Drug Administration (FDA). Read more...
May 05, 2021 · Medicare Insights Team
The Centers for Medicare and Medicaid Services (CMS) released Version 3.3 of the Workers’ Compensation Medicare Set-Aside Arrangement (WCMSA) Reference Guide, which clarifies how to calculate the seed money (initial deposit) in a structured WCMSA. Read more...
May 03, 2021 · Clinical Team
When injured persons receive physical therapy early in the claim, multiple industry data sources show use of opioids and other pain medications and surgeries are reduced along with time away from work. Read more...
April 28, 2021 · Clinical Team
The generic formulation of Hysingla® ER, hydrocodone bitartrate extended-release (ER) tablets, was released in March 2021 according to the U.S. Food and Drug Administration (FDA). Hysingla ER is FDA-approved for the treatment of severe pain in patients who require daily, around-the-clock, long-term opioid analgesic treatment. Read more...
     Next >>
Page 1 of 17

Subscribe today to receive our latest blogs, articles, podcasts and more.